Search
Streptococcus pneumoniae type 23F capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10292ApprovedInvestigationalStreptococcus pneumoniae type 23f capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 23F individually conjugate...
Mixtures: Prevnar 20, Prevnar 20Benzyl nicotinate
go.drugbank.com/drugs/DB15764InvestigationalMixtures: HOTFİX 100 MG/G + 10 MG/G KREM , 50 GRAM, THERMO RHEUMON 100 MG/G + 10 MG/G KREM, 50 GLG-100268
go.drugbank.com/drugs/DB01941ExperimentalLG-100268 is a retinoid X receptor (RXR) selective compound.
Palifosfamide
go.drugbank.com/drugs/DB05668InvestigationalPalifosfamide (ZIO-201) is a proprietary stabilized metabolite of ifosfamide. Ifosfamide has been shown to be effective in high doses in treating testicular cancer, sarcoma and lymphoma.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalEvinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.
INM005
go.drugbank.com/drugs/DB16499InvestigationalINM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). Additionally, a retrospective cohort study investigated the ef...
Cinaciguat
go.drugbank.com/drugs/DB16126InvestigationalCinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients
Jaktinib
go.drugbank.com/drugs/DB17545InvestigationalJaktinib is under investigation in clinical trial NCT04866056 (Jaktinib and Azacitidine in Treating Patients With MDS With MF or MDS/MPN With MF.).
Rislenemdaz
go.drugbank.com/drugs/DB12063InvestigationalMk 0657 has been used in trials studying the treatment of Major Depressive Disorder.
REP8839
go.drugbank.com/drugs/DB05224ExperimentalREP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).